Biotech
Beam Therapeutics
Beam Therapeutics raises $206M Series C at $3.5B valuation
$206M
Total Raised
Series C
Latest Round
2017
Founded
400+
Employees
238 Main Street, Cambridge, MA 02142
1 min read
Quick Facts
Valuation
$3.5B
Latest Round Size
$206M
Latest Round Date
May 2024
Beam Therapeutics: Series C Funding Round
Beam Therapeutics has successfully raised $206M in Series C funding, reaching a valuation of $3.5B.
Company Overview
Base editing technology
Funding Details
The Series C round was led by Foresite Capital, with participation from F-Prime Capital, Omega Funds, Redmile Group, Wellington Management.
Company Information
- Headquarters: 238 Main Street, Cambridge, MA 02142
- Founded: 2017
- Employees: 400+
- Category: Biotech
Investment
Beam Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Foresite Capital: Verified investor in Series C
- F-Prime Capital: Verified investor in Series C
- Omega Funds: Verified investor in Series C
- Redmile Group: Verified investor in Series C
- Wellington Management: Verified investor in Series C
Key Investors
Foresite Capital
Lead Investor
Verified investor in Series C
F-Prime Capital
Investor
Verified investor in Series C
Omega Funds
Investor
Verified investor in Series C
Redmile Group
Investor
Verified investor in Series C
Wellington Management
Investor
Verified investor in Series C
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min readβ’$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min readβ’$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min readβ’$250M